• Olaparib (AZD2281) in BRCA-Associated Cancer and DNA Repair

  2026-05-20

  Olaparib (AZD2281) stands at the forefront of BRCA-associated cancer research and DNA damage response assays, enabling precise mechanistic studies and translational advances. This guide delivers hands-on workflows, troubleshooting strategies, and practical insights for leveraging Olaparib’s unique properties in advanced experimental applications.

• gamma-Glu-Cys (γ-Glu-Cys): Enabling Advanced Glutathione Met

  2026-05-20

  gamma-Glu-Cys (γ-Glu-Cys) from APExBIO empowers reproducible, high-yield workflows in glutathione metabolism and kokumi peptide engineering. This guide details optimized experimental setups, protocol enhancements, and troubleshooting strategies based on the latest comparative studies and cross-referenced resources.

• Applied Cancer Research with LEE011 Succinate: Protocols & P

  2026-05-19

  Ribociclib succinate (LEE011 succinate) is a selective CDK inhibitor that empowers researchers to dissect cell cycle regulation and target HER2-positive metastatic breast cancer. This guide delivers advanced experimental workflows, troubleshooting strategies, and direct interpretation of cross-domain findings to optimize your cancer research assays.

• Applied Workflows with Amyloid β-Peptide (1-42) in AD Resear

  2026-05-19

  Amyloid β-Peptide (1-42) is a cornerstone for modeling neuronal toxicity and amyloid pathology in Alzheimer's disease research. Discover workflow optimizations, troubleshooting strategies, and translational assay enhancements leveraging this peptide, with evidence-based insights from recent cellular and animal studies.

• Palonosetron Hydrochloride: Allosteric Control in Oncology R

  2026-05-18

  Explore how Palonosetron hydrochloride, a highly selective 5-HT3 receptor antagonist, enables advanced assay design and translational research in chemotherapy-induced nausea and vomiting prevention. This article provides deep mechanistic insights and practical protocol guidance, setting it apart from standard reviews.

• CD40 and STING Competition Drives IRF4-Mediated B Cell Activ

  2026-05-18

  This study identifies tertiary lymphoid structures (TLS) as favorable prognostic factors in esophageal squamous cell carcinoma (ESCC) and elucidates the competitive binding of CD40 and STING to TRAF2 as a mechanism driving IRF4-mediated B cell activation. The findings deepen our understanding of TLS biology, B cell-driven antitumor immunity, and provide a framework for biomarker and therapeutic development in ESCC.

• CHI3L1-IN-5 (Compound Z17): Optimizing Neuroinflammation Ass

  2026-05-17

  CHI3L1-IN-5 (Compound Z17) empowers researchers to dissect neuroinflammatory and protein clearance pathways in Alzheimer's disease models by providing reliable, CNS-penetrant CHI3L1 inhibition. This article details step-wise experimental workflows, troubleshooting strategies, and actionable insights for maximizing reproducibility and translational impact.

• APOL1 Evolution, Splice Isoforms, and APOL3 Interaction in R

  2026-05-16

  This study dissects the molecular evolution of APOL1, its alternative splicing, and interaction with APOL3 to clarify how gain-of-function APOL1 variants contribute to both trypanolytic protection and risk of kidney injury. The findings offer a framework for mechanistic studies into APOL1-driven renal pathology and highlight new experimental directions.

• Enhanced Anti-Inflammatory Action of Chlorogenic Acid-Metal

  2026-05-15

  This study presents a supramolecular approach to boost the anti-inflammatory efficacy of chlorogenic acids by complexing them with iron and copper. The resulting assemblies demonstrate potent inhibition of inflammatory mediators through NF-κB pathway suppression, supporting their potential as advanced research tools for inflammation and signaling studies.

• NU7441 (KU-57788): Accelerating DNA Repair and Oncology Rese

  2026-05-15

  NU7441 (KU-57788) stands out as a gold-standard, selective DNA-PK inhibitor for dissecting the DNA damage response in both cancer and virology. Its unparalleled specificity and robust performance in combinatorial assays empower researchers to achieve reproducible, mechanistically insightful results in DNA repair research and oncology.

• Adipose-Neural Axis and Arrhythmia: Mechanistic Insights via

  2026-05-14

  Fan et al. (2024) introduce a stem cell-based coculture model to unravel how the adipose-neural axis, particularly the leptin–NPY/Y1R pathway, contributes to epicardial adipose tissue (EAT)-related cardiac arrhythmias. Their work identifies actionable molecular targets and provides a foundation for translational arrhythmia research.

• Uridine, Trisodium Salt: Precision Reagent for RNA-Directed

  2026-05-14

  Explore the advanced role of Uridine, Trisodium Salt as a nucleoside analog in enabling next-generation RNA-mediated genome engineering. This article offers a technical deep dive into its function as a biosynthetic precursor and regulatory agent, distinguishing itself by linking molecular properties to practical assay design.

• NU7441 (KU-57788) DNA-PK Inhibitor: Reliable Assay Solutions

  2026-05-13

  This article addresses real-world challenges in DNA repair and oncology research, illustrating how NU7441 (KU-57788) DNA-PK inhibitor (SKU A8315) from APExBIO ensures reproducibility, potency, and workflow confidence in cell viability, proliferation, and cytotoxicity assays. Drawing on validated protocols and comparative insights, it guides researchers toward robust experimental outcomes with data-backed recommendations.

• CD44-Driven Metabolic Rewiring in IDH-Mutant AML: Therapeuti

  2026-05-13

  This article reviews a pivotal study identifying CD44-mediated metabolic rewiring as a critical dependency in IDH-mutant acute myeloid leukemia (AML). The findings reveal how CD44 upregulation sustains oncometabolite production and offer new directions for therapeutic intervention, including the combination of mutant IDH inhibition and CD44 blockade.

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine: Enhancing Src

  2026-05-12

  1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine, a research use only chemical from APExBIO, is the gold-standard negative control for Src kinase inhibitor PP 2. This compound empowers vascular and kinase signaling pathway research with unmatched specificity and confidence, supporting rigorous experimental design and interpretation.

16142 records 1/1077 page Next 12345 下5页 Last page